Article
A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
BMC cancer - 27 Mar 2017
Lereclus Emilie, Tout Mira, Girault Alban, Baroukh Nadine, Caulet Morgane, Borg Christophe, Bouché Olivier, Ternant David, Paintaud Gilles, Lecomte Thierry, Raoul William
Abstract excerpt
BACKGROUND: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.